Javascript must be enabled to continue!
Histopathological features of idiopathic portal hypertension: A systematic review and meta-analysis
View through CrossRef
Background Portal hypertension (PH) is a clinically significant entity that could present with life-threatening gastrointestinal bleeding. Cirrhosis is the most common cause of PH, with well-documented histopathology and etiology. However, in idiopathic portal hypertension (IPH), no single histopathologic finding is associated with PH. Our systematic review aims to identify and summarize the prevalence of the common histological findings of IPH. Methods We systematically searched PubMed, Cochrane CENTRAL, Web of Science, and Scopus till 1ST March 2022 for studies describing the histopathological features of IPH. Data were extracted from eligible studies and pooled as events rate and 95% confidence interval (CI) using binary random-effects model by open meta-analyst software. Results We included 23 retrospective studies with a total sample size of 813 patients. The overall incidence of nodular regenerative hyperplasia was 38.6%, 59.8% for portal fibrosis, 51.3% for periportal fibrosis, 39.3% for perisinusoidal fibrosis, 89.8% for portal vein sclerosis, 42.2% for portal inflammation, 53.3% for mega-sinusoids, 39.5% for thickening of portal vein branches, 93.8% for narrowing of portal veins, 53.3% for hepatic veins/venous outflow obstruction, 51.4% for aberrant portal/periportal vessels, 42.4% for shunt vessel, 50.9% for ductular proliferation, and 16.3% for steatosis. Conclusion Due to the relatively non-pathognomonic and non-specific nature of IPH, a combination of different histological features such as the portal and periportal fibrosis, portal vein sclerosis, mega-sinusoids, narrowing of portal veins, hepatic venous outflow obstruction, aberrant portal or periportal vessels, and ductular proliferation may be of value in diagnosing IPH as the incidence rate of these features was at approximately 50%.
SAGE Publications
Title: Histopathological features of idiopathic portal hypertension: A systematic review and meta-analysis
Description:
Background Portal hypertension (PH) is a clinically significant entity that could present with life-threatening gastrointestinal bleeding.
Cirrhosis is the most common cause of PH, with well-documented histopathology and etiology.
However, in idiopathic portal hypertension (IPH), no single histopathologic finding is associated with PH.
Our systematic review aims to identify and summarize the prevalence of the common histological findings of IPH.
Methods We systematically searched PubMed, Cochrane CENTRAL, Web of Science, and Scopus till 1ST March 2022 for studies describing the histopathological features of IPH.
Data were extracted from eligible studies and pooled as events rate and 95% confidence interval (CI) using binary random-effects model by open meta-analyst software.
Results We included 23 retrospective studies with a total sample size of 813 patients.
The overall incidence of nodular regenerative hyperplasia was 38.
6%, 59.
8% for portal fibrosis, 51.
3% for periportal fibrosis, 39.
3% for perisinusoidal fibrosis, 89.
8% for portal vein sclerosis, 42.
2% for portal inflammation, 53.
3% for mega-sinusoids, 39.
5% for thickening of portal vein branches, 93.
8% for narrowing of portal veins, 53.
3% for hepatic veins/venous outflow obstruction, 51.
4% for aberrant portal/periportal vessels, 42.
4% for shunt vessel, 50.
9% for ductular proliferation, and 16.
3% for steatosis.
Conclusion Due to the relatively non-pathognomonic and non-specific nature of IPH, a combination of different histological features such as the portal and periportal fibrosis, portal vein sclerosis, mega-sinusoids, narrowing of portal veins, hepatic venous outflow obstruction, aberrant portal or periportal vessels, and ductular proliferation may be of value in diagnosing IPH as the incidence rate of these features was at approximately 50%.
Related Results
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
Pharmacogenomics and the Concept of Personalized Medicine for the Management of Hypertension
Pharmacogenomics and the Concept of Personalized Medicine for the Management of Hypertension
Hypertension poses a significant global burden due to low adherence to antihypertensive medications. Hypertension treatment aims to bring blood pressure within physiological ranges...
Do evidence summaries increase health policy‐makers' use of evidence from systematic reviews? A systematic review
Do evidence summaries increase health policy‐makers' use of evidence from systematic reviews? A systematic review
This review summarizes the evidence from six randomized controlled trials that judged the effectiveness of systematic review summaries on policymakers' decision making, or the most...
Editor's welcome, PORTAL, Vol. 1, No. 1, January 2004
Editor's welcome, PORTAL, Vol. 1, No. 1, January 2004
Welcome to the inaugural issue of PORTAL
On behalf of the Executive Editorial Committee of PORTAL Journal of Multidisciplinary International Studies, it is a great ple...
Brief Review of Portal Hypertension Related Complications
Brief Review of Portal Hypertension Related Complications
The pathologic increase in the pressure gradient between portal vein and inferior venacava is called portal hypertension. Increased portal blood flow and increased resistance in th...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract
Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

